Blueprint Medicines Corp (BPMC)
108.01
+1.01
(+0.94%)
USD |
NASDAQ |
May 03, 14:17
Blueprint Medicines Debt to Equity Ratio: 1.828 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
December 31, 2023 | 1.828 |
September 30, 2023 | 1.176 |
June 30, 2023 | 0.45 |
March 31, 2023 | 0.3367 |
December 31, 2022 | 0.2702 |
September 30, 2022 | 0.2161 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
Date | Value |
---|---|
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.0006 |
June 30, 2018 | 0.0013 |
March 31, 2018 | 0.0019 |
December 31, 2017 | 0.0024 |
September 30, 2017 | 0.0061 |
June 30, 2017 | 0.0071 |
March 31, 2017 | 0.0172 |
December 31, 2016 | 0.0191 |
September 30, 2016 | 0.05 |
June 30, 2016 | 0.0507 |
March 31, 2016 | 0.0503 |
December 31, 2015 | 0.051 |
September 30, 2015 | 0.0498 |
June 30, 2015 | 0.0487 |
March 31, 2015 | 0.35 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2019
1.828
Maximum
Dec 2023
0.2252
Average
--
Median
Jun 2019
Debt to Equity Ratio Benchmarks
Alnylam Pharmaceuticals Inc | -4.626 |
Apellis Pharmaceuticals Inc | 0.4783 |
Ionis Pharmaceuticals Inc | 3.317 |
Madrigal Pharmaceuticals Inc | -- |
Sarepta Therapeutics Inc | 1.289 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 1.049B |
Total Liabilities (Quarterly) | 918.64M |
Shareholders Equity (Quarterly) | 130.61M |
Current Ratio | 3.761 |
Net Debt Paydown Yield | -0.36% |